Group 1 - The company, Chaoyujian Ophthalmology (02219), announced a share buyback plan, intending to repurchase 60,000 shares at a cost of approximately HKD 158,900 on January 15, 2026 [1]

Group 1 - The company, Chaoyou Eye Care (02219.HK), announced a share buyback on January 15, 2023, spending HKD 159,000 to repurchase 60,000 shares at a price range of HKD 2.63 to HKD 2.67 per share [1]

登录新浪财经APP 搜索【信披】查看更多考评等级 本公司及董事会全体成员保证信息披露内容的真实、准确和完整，没有虚假记载、误导性陈述或重大遗 漏。 重要提示： 1.本次股东会无增加、变更、否决提案的情况。 2.本次股东会以现场与网络投票相结合的方式召开。 一、会议召开和出席情况 辽宁何氏眼科医院集团股份有限公司（以下简称"公司"）2026年第一次临时股东会于2026年1月14日召 开，公司董事会已于2025年12月25日在巨潮资讯网上刊登了《关于召开2026年第一次临时股东会的通 知》。 本次股东会由公司董事会召集，现场会议由公司董事长何伟先生主持，会议召开符合《公司法》《上市 公司股东会规则》《深圳证券交易所创业板股票上市规则》及《公司章程》等规定。 1.会议召开方式：本次股东会采用现场和网络投票相结合的方式召开。 2.会议召开日期和时间： 出席本次股东会的股东及其股东代表均为2026年1月7日（星期三）下午深圳证券交易所收市时，在中国 证券登记结算有限责任公司深圳分公司登记在册的公司普通股股东。 （1）股东出席的总体情况 通过现场和网络投票的股东84人，代表股份87,746,065股，占公司有表决权股份总 ...

Core Viewpoint - Huaxia Eye Hospital announced the election of Mr. Zhang Guangbin as the employee representative director of the fourth board of directors during the first employee representative meeting scheduled for January 14, 2026 [2] Group 1 - The company will hold its first employee representative meeting on January 14, 2026 [2] - Mr. Zhang Guangbin has been elected as the employee representative director [2]

Group 1 - The company is steadily advancing its "smart hospital" construction [1] - The company continues to pay attention to new developments in cutting-edge interdisciplinary fields [1]

Group 1 - The company has continued to provide high-quality ophthalmic medical services and has become the only center in Hong Kong offering a comprehensive advanced refractive treatment product portfolio, including LASIK, SMILE, SMILE Pro, SILKTM, and ICL, solidifying its technological leadership in the market [1] - The company's business performance has remained stable, with a gradual recovery in operational performance by the end of 2025, as evidenced by patient visits, new patient appointments, and surgical volumes reaching or exceeding levels from the same period in the past two years [1] - The company ranked first in Hong Kong for ICL surgeries in 2025, achieving the industry's top position for the third consecutive year [1] Group 2 - The company has incurred significant professional fees exceeding HKD 15 million due to ongoing allegations against former directors, which have created a substantial financial burden that could have been allocated to business development and enhancing shareholder returns [1] - The company is committed to efficiently completing the investigation related to the allegations and accelerating the resumption of its shares, allowing management to refocus on executing its long-term strategic priorities [1] - The latest resumption guidance includes various directives such as investigation and rectification guidelines, integrity guidelines, internal control guidelines, corporate governance guidelines, disclosure guidelines, financial reporting guidelines, and compliance with Article 13.24 [2]

Core Viewpoint - Clear Medical (01406.HK) has established itself as the only ophthalmic center in Hong Kong offering a comprehensive advanced refractive treatment portfolio, solidifying its technological leadership in the market [1] Group 1: Company Performance - The company has continued to provide high-quality ophthalmic medical services over the past few months [1] - After a period of slightly weak performance, operational metrics began to recover by the end of 2025, with December seeing patient visits, new patient appointments, and surgical volumes reaching or exceeding levels from the same period in the past two years [1] - The company ranked first in Hong Kong for ICL surgeries in 2025, marking its third consecutive year as the industry leader [1] Group 2: Strategic Developments - The company is set to officially launch the SILK refractive surgery platform in collaboration with Johnson & Johnson in November 2025 [1] - The introduction of the SILK platform enhances the company's offerings, which include LASIK, SMILE, SMILEPro, SILKTM, and ICL [1]

Group 1 - The core viewpoint of the article highlights that Clear Medical (01406) has established itself as the only ophthalmic center in Hong Kong offering a comprehensive advanced refractive treatment product portfolio, further solidifying its technological leadership in the market [1] - The company's business performance has shown resilience, with patient visits, new patient appointments, and surgical volumes in December 2025 reaching or exceeding levels from the same period in the past two years [1] - Clear Medical ranked first in Hong Kong for ICL surgeries in 2025, marking the third consecutive year of industry leadership [1] Group 2 - The company has incurred significant professional fees exceeding HKD 15 million due to ongoing allegations against former directors, which have created a substantial financial burden that could have been allocated to business development and shareholder returns [1] - The company is committed to efficiently completing the investigation related to the allegations and expediting the resumption of its shares, allowing management to refocus on executing its long-term strategic priorities [1] - The latest resumption guidelines include directives on investigation and rectification, integrity, internal controls, corporate governance, disclosure, financial reporting, and compliance with specific regulations [2]

Core Viewpoint - The "2026 Maritime Light" academic conference on optometry and visual science highlighted Huaxia Eye Hospital's achievements in refractive surgery, showcasing its innovative practices and clinical quality, which earned multiple prestigious awards [1][4][24]. Group 1: Awards and Recognition - Huaxia Eye Hospital received the "High-Quality Development Contribution Award" for performing over 7,000 new SMILE pro surgeries, reflecting its commitment to standardized, safe, and high-quality surgical practices [4]. - The Xiamen University Affiliated Xiamen Eye Center completed over 3,500 surgeries, while Chengdu Aidi Eye Hospital and Zhengzhou Huaxia Vision Eye Hospital completed over 1,500 and 1,300 surgeries respectively, earning them the "High-Quality Development Contribution Award" for exceeding 1,000 cases [8]. - Huaxia Eye Hospital was recognized with the "Non-Public Medical EVO ICL Project Innovation Breakthrough Award" for its extensive experience and advancements in ICL technology since 2010 [15]. Group 2: Technological Advancements - The hospital introduced the new EVO+ ICL (V5) technology, establishing a nationwide clinical application network and enhancing its leadership in refractive surgery [12]. - The launch of the "Large Optical Zone Intraocular Lens ICL (V5)" technology was a significant milestone, showcasing Huaxia Eye Hospital's expertise and experience in the field [11]. Group 3: Academic Contributions - Huaxia experts actively participated in various academic sessions, demonstrating their influence and technical capabilities in the field of refractive surgery [23]. - The hospital's commitment to academic exchange was evident through its involvement in specialized discussions and practical training sessions during the conference [21][23]. Group 4: Strategic Development - Huaxia Eye Hospital's success is attributed to over 20 years of dedication in the refractive surgery field, focusing on the integration of technology, talent, platform, and service [24]. - The hospital aims to enhance its dual strategy of "corneal laser surgery" and "intraocular lens surgery," accelerating the clinical research of EVO+ ICL (V5) and expanding the application of advanced technologies like new SMILE pro and all-light shaping [24].

Group 1 - Core viewpoint: Puri Eye Hospital has seen a continuous increase in stock price, with a 5-day cumulative increase of 5.84% as of January 14, reaching a price of 34.26 yuan per share and a total market capitalization of 5.126 billion yuan [1] - Company overview: Puri Eye Hospital Group Co., Ltd. was established on March 23, 2006, and went public on July 5, 2022. The company provides comprehensive medical services for eye diseases, including diagnosis, treatment, healthcare, and optical services [1] - Revenue composition: The main business revenue is derived from refractive projects (49.36%), cataract projects (19.77%), comprehensive eye disease projects (16.65%), vision projects (13.03%), and other services (1.18%) [1] Group 2 - Shareholder information: The Rongtong Health Industry Flexible Allocation Mixed A/B Fund (000727) is among the top ten circulating shareholders of Puri Eye Hospital, having reduced its holdings by 192,500 shares in the third quarter, now holding 2.4 million shares, which is 1.69% of the circulating shares [2] - Fund performance: The Rongtong Health Industry Flexible Allocation Mixed A/B Fund has achieved a year-to-date return of 9.61% and a one-year return of 26.99%, ranking 782 out of 8,838 and 4,859 out of 8,089 respectively [2] - Fund manager details: The fund manager, Wan Minyuan, has a tenure of 9 years and 144 days, with a total fund asset size of 5.957 billion yuan and a best return of 149.74% during his tenure [2]